These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 33328215)

  • 41. The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells.
    Dixit D; Prager BC; Gimple RC; Poh HX; Wang Y; Wu Q; Qiu Z; Kidwell RL; Kim LJY; Xie Q; Vitting-Seerup K; Bhargava S; Dong Z; Jiang L; Zhu Z; Hamerlik P; Jaffrey SR; Zhao JC; Wang X; Rich JN
    Cancer Discov; 2021 Feb; 11(2):480-499. PubMed ID: 33023892
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
    Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
    Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
    [TBL] [Abstract][Full Text] [Related]  

  • 43. ZNF117 regulates glioblastoma stem cell differentiation towards oligodendroglial lineage.
    Liu J; Wang X; Chen AT; Gao X; Himes BT; Zhang H; Chen Z; Wang J; Sheu WC; Deng G; Xiao Y; Zou P; Zhang S; Liu F; Zhu Y; Fan R; Patel TR; Saltzman WM; Zhou J
    Nat Commun; 2022 Apr; 13(1):2196. PubMed ID: 35459228
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours.
    Larson RC; Kann MC; Bailey SR; Haradhvala NJ; Llopis PM; Bouffard AA; Scarfó I; Leick MB; Grauwet K; Berger TR; Stewart K; Anekal PV; Jan M; Joung J; Schmidts A; Ouspenskaia T; Law T; Regev A; Getz G; Maus MV
    Nature; 2022 Apr; 604(7906):563-570. PubMed ID: 35418687
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma.
    Martínez Bedoya D; Dutoit V; Migliorini D
    Front Immunol; 2021; 12():640082. PubMed ID: 33746981
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mesenchymal and Proneural Subtypes of Glioblastoma Disclose Branching Based on GSC Associated Signature.
    Steponaitis G; Tamasauskas A
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34066996
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neoantigen discovery and applications in glioblastoma: An immunotherapy perspective.
    Wang C; Yu M; Zhang W
    Cancer Lett; 2022 Dec; 550():215945. PubMed ID: 36216148
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Current Molecular Advancements in Chimeric Antigen Receptor (CAR-T) Cells for the Treatment of Leukemia.
    Bangit LEP; Derwich K
    J Adolesc Young Adult Oncol; 2022 Aug; 11(4):346-351. PubMed ID: 34935501
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57.
    Zhu X; Prasad S; Gaedicke S; Hettich M; Firat E; Niedermann G
    Oncotarget; 2015 Jan; 6(1):171-84. PubMed ID: 25426558
    [TBL] [Abstract][Full Text] [Related]  

  • 50. T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells.
    Yang D; Sun B; Dai H; Li W; Shi L; Zhang P; Li S; Zhao X
    J Immunother Cancer; 2019 Jul; 7(1):171. PubMed ID: 31288857
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chimeric antigen receptor T cell therapy and other therapeutics for malignancies: Combination and opportunity.
    Wang L; Yao R; Zhang L; Fan C; Ma L; Liu J
    Int Immunopharmacol; 2019 May; 70():498-503. PubMed ID: 30875561
    [TBL] [Abstract][Full Text] [Related]  

  • 52. REST-DRD2 mechanism impacts glioblastoma stem cell-mediated tumorigenesis.
    Marisetty AL; Lu L; Veo BL; Liu B; Coarfa C; Kamal MM; Kassem DH; Irshad K; Lu Y; Gumin J; Henry V; Paulucci-Holthauzen A; Rao G; Baladandayuthapani V; Lang FF; Fuller GN; Majumder S
    Neuro Oncol; 2019 Jun; 21(6):775-785. PubMed ID: 30953587
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.
    Morgan RA; Johnson LA; Davis JL; Zheng Z; Woolard KD; Reap EA; Feldman SA; Chinnasamy N; Kuan CT; Song H; Zhang W; Fine HA; Rosenberg SA
    Hum Gene Ther; 2012 Oct; 23(10):1043-53. PubMed ID: 22780919
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting of BMI-1 with PTC-209 inhibits glioblastoma development.
    Kong Y; Ai C; Dong F; Xia X; Zhao X; Yang C; Kang C; Zhou Y; Zhao Q; Sun X; Wu X
    Cell Cycle; 2018; 17(10):1199-1211. PubMed ID: 29886801
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens.
    Rapp C; Warta R; Stamova S; Nowrouzi A; Geisenberger C; Gal Z; Roesch S; Dettling S; Juenger S; Bucur M; Jungk C; DaoTrong P; Ahmadi R; Sahm F; Reuss D; Fermi V; Herpel E; Eckstein V; Grabe N; Schramm C; Weigand MA; Debus J; von Deimling A; Unterberg A; Abdollahi A; Beckhove P; Herold-Mende C
    Acta Neuropathol; 2017 Aug; 134(2):297-316. PubMed ID: 28332095
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MiR-449a exerts tumor-suppressive functions in human glioblastoma by targeting Myc-associated zinc-finger protein.
    Yao Y; Ma J; Xue Y; Wang P; Li Z; Li Z; Hu Y; Shang X; Liu Y
    Mol Oncol; 2015 Mar; 9(3):640-56. PubMed ID: 25487955
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Non-invasive monitoring of the kinetic infiltration and therapeutic efficacy of nanoparticle-labeled chimeric antigen receptor T cells in glioblastoma via 7.0-Tesla magnetic resonance imaging.
    Xie T; Chen X; Fang J; Xue W; Zhang J; Tong H; Liu H; Guo Y; Yang Y; Zhang W
    Cytotherapy; 2021 Mar; 23(3):211-222. PubMed ID: 33334686
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Myelin-forming cell-specific cadherin-19 is a marker for minimally infiltrative glioblastoma stem-like cells.
    Zorniak M; Clark PA; Kuo JS
    J Neurosurg; 2015 Jan; 122(1):69-77. PubMed ID: 25361488
    [TBL] [Abstract][Full Text] [Related]  

  • 59. TRIM8 regulates stemness in glioblastoma through PIAS3-STAT3.
    Zhang C; Mukherjee S; Tucker-Burden C; Ross JL; Chau MJ; Kong J; Brat DJ
    Mol Oncol; 2017 Mar; 11(3):280-294. PubMed ID: 28100038
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell.
    Jiang H; Gao H; Kong J; Song B; Wang P; Shi B; Wang H; Li Z
    Cancer Immunol Res; 2018 Nov; 6(11):1314-1326. PubMed ID: 30201736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.